Product
Nucleos(t)ide analogue
1 clinical trial
2 indications
Indication
Chronic Hepatitis BIndication
Hepatocellular Carcinoma (HCC)Clinical trial
A Prospective, Randomized, Open-label, Multicenter Study to Evaluate the Peginterferon, Comparing to Nucleos(t)Ide Analogues, in Reducing the Incidence of HCC in Chronic Hepatitis B Patients With Intermediate to High Liver Cancer RisksStatus: Recruiting, Estimated PCD: 2023-08-01